Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ear zaps may tune your nervous system – scientists test best frequency

NCT ID NCT07526402

Knowledge-focused Sponsor: Sinop University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will test how stimulating the ear with mild electrical pulses at different frequencies affects heart rate, breathing, and blood pressure in 36 healthy adults. Each person will try five different stimulation settings (including a fake one) in separate sessions. The goal is to see which frequency most strongly influences the body's 'rest and digest' system.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcutaneous auricular vagus nerve stimulation (taVNS)
What this could lead to
If successful, this could help identify the best stimulation frequency for future treatments of conditions like anxiety, epilepsy, or depression.
What could go wrong
This is a small, early-stage study in healthy volunteers, not patients. Results may not apply to real-world medical conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adults aged 18 to 40 years * No known neurological, cardiovascular, respiratory, or metabolic disease * Able to understand study procedures and provide written informed consent * No active infection, open wound, or dermatological lesion in the ear region that would interfere with taVNS application * Willing and able to attend all study visits Exclusion Criteria: * History of cardiac arrhythmia, pacemaker, or any implanted electronic medical device History of hypertension, diabetes, chronic pulmonary disease, epilepsy, or systemic disease affecting autonomic nervous system function * Regular use of medications that may affect autonomic function (e.g., beta-blockers, antidepressants, antiarrhythmics) * Intense physical exercise within the previous 24 hours * High caffeine or alcohol intake within 12 hours prior to assessment * Active smoking on the assessment day * Pregnancy or suspected pregnancy * Severe discomfort during stimulation (VAS \>= 7), dizziness, nausea, or unwillingness to continue * Any condition judged by the investigators to make participation unsuitable'

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic nervous system response are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autonomic nervous system response Healthy volunteers Heart rate variability

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Artvin Coruh University, Artvin Vocational School, Disabled Care and Rehabilitation Laboratory

    Artvin, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.